C3441052 Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC

NCT04821622

Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC

Associated Conditions

Prostate Cancer

Principal Investigator

Sponsor

Pfizer Inc.

This study will explore the safety and the efficacy (how well it works) of an investigational drug talazoparib, when added to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC).

This study is currently enrolling.